.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
UBS
Medtronic
Healthtrust
Julphar
Accenture
Teva
Baxter
Merck
Dow

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,763,454

« Back to Dashboard

Summary for Patent: 5,763,454

Title: Crystal form of anhydrous 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-f luoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt
Abstract:The anhydrate of 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-flu oro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt has advantageous stability for formulation as an antibacterial agent.
Inventor(s): Handanyan; Lynne A. (New York, NY), Morris; Thomas A. (New York, NY), Hendrickson; Robert L. (New York, NY), Johnson; Phillip J. (New York, NY), Norris; Timothy (New York, NY)
Assignee: Pfizer, Inc. (New York, NY)
Application Number:08/849,300
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,763,454

PCT Information
PCT FiledJune 06, 1995PCT Application Number:PCT/US95/07211
PCT Publication Date:December 12, 1996PCT Publication Number: WO96/39406

International Patent Family for Patent: 5,763,454

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Iceland4351► Subscribe
Czech Republic9601625► Subscribe
Czech Republic285878► Subscribe
Germany69503066► Subscribe
Denmark0789697► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
McKinsey
AstraZeneca
Harvard Business School
Julphar
Teva
Cerilliant
Deloitte
Federal Trade Commission
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot